Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.

Oncotarget - 27 Dec 2016

Biaoxue Rong, Hua Liu, Wenlong Gao, Shuanying Yang

Abstract excerpt

Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China; this work was to evaluate its efficacy and safety in treating non-small cell lung cancer (NSCLC). Clinical studies evaluating the efficacy and safety of icotinib in treating NSCLC were identified from the databases of Medline, Web of Science, Embase and Cochrance Library. Pooled efficacy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Crown Ethers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Disease-Free Survival

Share to Exanthema

Share to Protein Kinase Inhibitors

Share to Pruritus

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 27893423
DOI: 10.18632/oncotarget.13509
PMCID: PMC5349962

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.PMID 27893423Read ↗

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.Semantic proximity Read ↗

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

[The therapeutic value and safety of icotinib as first-line therapy for advanced non-small cell lung cancer patients].Semantic proximity Read ↗

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].Semantic proximity Read ↗

[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].Semantic proximity Read ↗

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].Semantic proximity Read ↗

Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.Semantic proximity Read ↗

Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.Semantic proximity Read ↗

Status and progress of Icotinib in treatment of EGFR-mutant non-small cell lung carcinomaSemantic proximity Read ↗

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.Semantic proximity Read ↗

[Clinical Analysis of Icotinib on Beneficiary of Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.